Literature DB >> 18019800

Valvular heart disease: diagnosis and management.

Suman Bhandari1, K Subramanyam, N Trehan.   

Abstract

Valvular heart disease is a leading cause of morbidity and mortality in India. Advances in both surgical and percutaneous techniques and a better understanding of timing for intervention accounts for the current increased rates of survival. Echocardiography remains the gold standard for diagnosis and periodic assessment of patients with valvular heart disease. Generally, patients with stenotic valvular lesions can be monitored clinically until symptoms appear and most can now benefit from percutaneous techniques. In contrast, patients with regurgitant valvular lesions require careful echocardiographic monitoring for left ventricular function and may require surgery even if no symptoms are present. Percutaneous therapy of valvular regurgitant lesions is yet to evolve fully.

Entities:  

Mesh:

Year:  2007        PMID: 18019800

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  3 in total

1.  The Safety and Efficacy of Low-Molecular-Weight Heparin in Pregnant Women With Rheumatic Heart Disease and Valves Replacement.

Authors:  Najwa Alghamdi; Saeed Alqahtani; Lujain Allehyani; Haifa Alosaimi; Waleed Almutairi; Saleh Alobaid; Hanan B Albackr; Latifah Aldakhil; Ghazi S Alotaibi; Farjah H Alqahtani
Journal:  Cureus       Date:  2022-03-11

2.  A review of outcome following valve surgery for rheumatic heart disease in Australia.

Authors:  E Anne Russell; Lavinia Tran; Robert A Baker; Jayme S Bennetts; Alex Brown; Christopher M Reid; Robert Tam; Warren F Walsh; Graeme P Maguire
Journal:  BMC Cardiovasc Disord       Date:  2015-09-23       Impact factor: 2.298

3.  A review of valve surgery for rheumatic heart disease in Australia.

Authors:  Elizabeth Anne Russell; Lavinia Tran; Robert A Baker; Jayme S Bennetts; Alex Brown; Christopher Michael Reid; Robert Tam; Warren Frederick Walsh; Graeme Paul Maguire
Journal:  BMC Cardiovasc Disord       Date:  2014-10-02       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.